You are here

  • Home
  • Archive
  • Volume 95, Issue 7
  • Response to ‘Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017’ by Checchi et al

Article Text

Article menu
Download PDFPDF
Miscellaneous
Letter
Response to ‘Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017’ by Checchi et al
  1. Valérie Berlaimont1,
  2. Sarah Welby2
  1. 1 Global Medical Affairs, GSK, Wavre, Belgium
  2. 2 Clinical and Epidemiology Research & Development, GSK, Wavre, Belgium
  1. Correspondence to Dr Valérie Berlaimont, GSK, Wavre 1300, Belgium; valerie.x.berlaimont{at}gsk.com

https://doi.org/10.1136/sextrans-2019-054101

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In England, although not anticipated, a reduction in genital warts (GW) diagnoses was observed from the first years of the human papillomavirus (HPV) vaccination programme using the adjuvanted bivalent vaccine, suggesting potentially cross-protective effect of the vaccine against GW.1

    In their recent publication, Checchi et al 2 present results of the GW surveillance programme in England since introduction of the HPV vaccination in 2008, attributing most of the impact observed today to the switch from the bivalent to the quadrivalent …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors Both authors participated in the analysis and interpretation of the data and the development of this letter. Both had full access to the data and gave final approval before submission.

    • Competing interests VB and SW are employees of the GSK group of companies. VB also holds shares in the GSK group of companies. GlaxoSmithKline Biologicals SA took in charge all costs associated with the development and publication of this short letter.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.